SLS BIO Co (XKRX:246250) Debt-to-Equity : 0.00 (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is SLS BIO Co Debt-to-Equity?

SLS BIO Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩0 Mil. SLS BIO Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩0 Mil. SLS BIO Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₩13,226 Mil. SLS BIO Co's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for SLS BIO Co's Debt-to-Equity or its related term are showing as below:

XKRX:246250' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.16 Med: 0.29 Max: 0.38
Current: 0.16

During the past 9 years, the highest Debt-to-Equity Ratio of SLS BIO Co was 0.38. The lowest was 0.16. And the median was 0.29.

XKRX:246250's Debt-to-Equity is ranked better than
62.18% of 193 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.23 vs XKRX:246250: 0.16

SLS BIO Co Debt-to-Equity Historical Data

The historical data trend for SLS BIO Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SLS BIO Co Debt-to-Equity Chart

SLS BIO Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

1.30

1.35

1.25

0.38

0.16

SLS BIO Co Quarterly Data
	Sep22	Dec22	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial			0.38	0.30	0.28	0.16	-

Competitive Comparison of SLS BIO Co's Debt-to-Equity

For the Diagnostics & Research subindustry, SLS BIO Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SLS BIO Co's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, SLS BIO Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where SLS BIO Co's Debt-to-Equity falls into.

SLS BIO Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

SLS BIO Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(568.263	+	1536.327)	/	13466.227
	=	0.16

SLS BIO Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	13225.723
	=	0.00

SLS BIO Co (XKRX:246250) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

SLS BIO Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of SLS BIO Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

SLS BIO Co (XKRX:246250) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SLS BIO Co Ltd (XKRX:246250) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Gwanggyo Central Biz Tower, 7th floor, Changryong-dong 260, Gyeonggi-do, Suwon-si, KOR, 16229

Website

http://www.slabs.co.kr

SLS BIO Co Ltd is engaged in providing drug development supporting services and pharmaceutical product QC through general tests and assays and instrumental analysis.

SLS BIO Co (XKRX:246250) Headlines

No Headlines